ENVVENO MEDICAL CORP (NVNO) Stock News

USA - NASDAQ:NVNO - US29415J1060 - Common Stock

0.968 USD

+0.02 (+1.73%)

Last: 10/3/2025, 8:00:02 PM

0.97 USD

+0 (+0.21%)

After Hours: 10/3/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NVNO Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: ACCESS Newswire

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

19 days ago - By: ACCESS Newswire

enVVeno Medical Updates Regulatory Status of VenoValve(R)

a month ago - By: Stocktwits - Mentions: VTI IWC

News Image

This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It?

2 months ago - By: ACCESS Newswire

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

2 months ago - By: ACCESS Newswire

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: ACCESS Newswire

enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

a month ago - By: Benzinga - Mentions: PTIX AEMD THAR APM ...

12 Health Care Stocks Moving In Thursday's Intraday Session

a month ago - By: Benzinga - Mentions: NBY TRIB WINT THAR ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

5 months ago - By: ACCESS Newswire

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

6 months ago - By: ACCESS Newswire

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

7 months ago - By: ACCESS Newswire

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

8 months ago - By: ACCESS Newswire

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

a month ago - By: ACCESS Newswire

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

2 months ago - By: ACCESS Newswire

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

2 months ago - By: ACCESS Newswire

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

2 months ago - By: ACCESS Newswire - Mentions: AKTX AMIX CNSP GRI ...

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

4 months ago - By: ACCESS Newswire

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

5 months ago - By: ACCESS Newswire

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

5 months ago - By: ACCESS Newswire

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

5 months ago - By: ACCESS Newswire

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

6 months ago - By: ACCESS Newswire

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

8 months ago - By: ACCESS Newswire

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum